Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

Lancet

Volumn 362, Issue 9382, 2003, Pages 428-432

  Scarabin, Pierre Yves ^a   Oger, Emmanuel ^b   Plu Bureau, Geneviève ^a  

^a INSERM   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOCUMENTATION; ESTROGEN THERAPY; FEMALE; HUMAN; IDIOPATHIC DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PRIORITY JOURNAL; RISK; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0042737410     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14066-4     Document Type: Article

References (24)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA. 288:2002;321-333.
2. Caine Y.G., Bauer K.A., Barzegar S. Coagulation activation following estrogen administration in postmenopausal women. Thromb Haemost. 68:1992;392-395.
3. Initial findings leading to modifications of its research protocol. JAMA. 214:1970;1303-1313.
4. Miller J., Chan B.K., Nelson H.D. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med. 136:2002;680-690.
5. Jick H., Derby L.E., Myers M.W., Vasilakis C., Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 348:1996;981-983.
6. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 348:1996;977-980.
7. Grodstein F., Stampfer M.J., Goldhaber S.Z., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348:1996;983-987.
8. Perez-Gutthann S., Garcia Rodriguez L.A., Castellsague J., Duque O.A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 314:1997;796-800.
9. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 147:1998;387-390.
10. Hoibraaten E., Abdelnoor M., Sandset P.M. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost. 82:1999;1218-1221.
11. Beral V., Banks E., Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet. 360:2002;942-944.
12. Oger E., Scarabin P.Y. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy. Drugs Aging. 14:1999;55-61.
13. Scarabin P.Y., Alhenc-Gelas M., Plu-Bureau G., Taisne P., Agher R., Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 17:1997;3071-3078.
14. Jick H., Vessey M.P. Case-control studies in the evaluation of drug-induced illness. Am J Epidemiol. 107:1978;1-7.
15. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA. 263:1990;2753-2759.
16. De Lignieres B., Basdevant A., Thomas G., et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab. 62:1986;536-541.
17. Powers M.S., Schenkel L., Darley P.E., Good W.R., Balestra J.C., Place V.A. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 152:1985;1099-1106.
18. Scott R.T., Ross B., Anderson C., Archer D.F. Pharmacokinetics of percutaneous estradiol: a cross-over study using a gel and a transdermal system in comparison with oral micronised estradiol. Obstet Gynecol. 77:1991;758-764.
19. Teede H.J., McGrath B.P., Smolich J.J., et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol. 20:2000;1404-1409.
20. Conard J., Samama M., Basdevant A., Guy-Grand B., De Lignières B. Differential AT III response to oral and parenteral administration of 17-beta estradiol. Thromb Haemost. 49:1983;252.
21. Hoibraaten E., Mowinckel M.C., de Ronde H., Bertina R.M., Sandset P.M. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol. 115:2001;415-420.
22. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomised trial. Arterioscler Thromb Vasc Biol 2003 (in press).
23. Seradour B., Esteve J., Heid P., Jacquemier J. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen. 6:1999;99-102.
24. Le Gal G., Gourlet V., Hogrel P., Plu-Bureau G., Touboul P.J., Scarabin P.Y. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis. 166:2003;163-170.